PubRank

Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid (GAMA)

Clinical Trial ID NCT02608736

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02608736

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999 9.53
2 Epigenetics in cancer. Carcinogenesis 2009 7.49
3 Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001 6.85
4 Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007 3.27
5 Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008 1.74
6 Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005 1.26
7 Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 2005 1.24
8 Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010 1.09
9 Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 2014 1.08
10 Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer 2014 1.01
11 Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. Cancer Prev Res (Phila) 2014 0.97
12 Study of bioequivalence of magnesium and sodium valproates. J Pharm Biomed Anal 1991 0.90
13 Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck 2011 0.90
14 Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clin Epigenetics 2011 0.84
15 Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol 2008 0.83
Next 100